Sanofi and Cipla enters into distribution partnership to expand reach of CNS portfolio in India
Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium
Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium
WINREVAIR is a breakthrough biologic for this rare, progressive disease
The inspection at Unit 1 by the USFDA has been successfully completed, with no observations under Form 483
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
Combination shows consistent benefit across prespecified post-progression outcomes
Operations of Line II was stopped due to a fire incident earlier
Hepatitis B infects over 40 million people in India
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
Subscribe To Our Newsletter & Stay Updated